New pill combo shows promise in slowing advanced breast cancer
NCT ID NCT02763566
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 trial tests whether adding the drug abemaciclib to standard hormone therapies (anastrozole, letrozole, or fulvestrant) can help slow cancer growth in postmenopausal women with a common type of advanced breast cancer (HR+, HER2-). About 463 women participated, and the main goal was to see how long the cancer stayed under control. The study is now complete and not recruiting new participants.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
abemaciclib (a CDK4/6 inhibitor) combined with anastrozole, letrozole, or fulvestrant
What this could lead to
If successful, this could provide a new treatment option that delays cancer progression for postmenopausal women with HR+, HER2- advanced breast cancer.
What could go wrong
This is a phase 3 trial, but results are not yet final. The drug may not improve survival for all patients and can cause side effects like diarrhea, fatigue, and low blood cell counts.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Afflilated Hospital of Bengbu Medical College
Bengbu, Anhui, 233004, China
-
Beijing Cancer Hospital
Beijing, Beijing Municipality, 100142, China
-
Centro Gaucho Integrado De Oncologia, Hematologia, Ensino E Pesquisa
Porto Alegre, Rio Grande do Sul, 90110-270, Brazil
-
Christian Medical College Vellore
Ranipet, Tamil Nadu, 632513, India
-
Clínica de Pesquisa e Centro de Estudos em Ginecologia Oncológica e Mamária LTDA
São Paulo, 01317-000, Brazil
-
Dr. B. L. Kapur Memorial Hospital
New Delhi, National Capital Territory of Delhi, 110005, India
-
Eastleigh Breast Care Center
Pretoria, Gauteng, 0081, South Africa
-
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, 200032, China
-
Fujian Provincial Cancer hospital
Fuzhou, Fujian, 350014, China
-
Fundação Pio XII - Hospital de Câncer de Barretos
Barretos, São Paulo, 14784-400, Brazil
-
Fuzhou General hospital of Nanjing Military Command
Fuzhou, Fujian, 350025, China
-
Guangdong Province People's Hospital
Guangzhou, Guangdong, 510080, China
-
Guangxi Medical University Affiliated Tumor Hospital
Nanning, Guangxi, 530021, China
-
Harbin Medical University Caner Hospital
Harbin, Heilongjiang, 150081, China
-
Healthcare Global Enterprises Limited (HCG)
Bangalore, Karnataka, 560027, India
-
Henan Cancer Hospital
Zhengzhou, Henan, 450008, China
-
Hospital de Base de Sao Jose do Rio Preto
São José do Rio Preto, São Paulo, 15091-000, Brazil
-
Hubei Cancer Hospital
Wuhan, Hubei, 430079, China
-
Hunan Cancer Hospital
Changsha, Hunan, 410013, China
-
Icesp - Instituto Do Câncer Do Estado de São Paulo
São Paulo, 01246-000, Brazil
-
Jehangir Hospital
Pune, Maharashtra, 411001, India
-
Jiangsu Cancer Hospital
Nanjing, Jiangsu, 210009, China
-
Jiangsu Province Hospital
Nanjing, Jiangsu, 210029, China
-
Jilin Province Tumor Hospital
Changchun, Jilin, 130012, China
-
Liaoning Cancer Hospital&Institute
Shenyang, Liaoning, 100042, China
-
M S Ramaiah Medical College Hospitals
Bangalore, Karnataka, 560054, India
-
Medica Superspecialty Hospital
Kolkata, West Bengal, 700099, India
-
Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School
Nanjing, Jiangsu, 210000, China
-
ONCOSITE - Centro de Pesquisa Clinica em Oncologia
Ijuí, Rio Grande do Sul, 98700 000, Brazil
-
Sandton Oncology Centre
Johannesburg, 2196, South Africa
-
Shanghai General Hospital
Shanghai, Shanghai Municipality, 200080, China
-
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University
Guangzhou, Guangdong, 510120, China
-
Tata Memorial Hospital
Mumbai, Maharashtra, 400 012, India
-
The 2nd Affiliated Hospital of Dalian Medical University
Dalian, Liaoning, 116023, China
-
The Fifth Medical Center of PLA General Hospital
Beijing, Beijing Municipality, 100071, China
-
The First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, Shaanxi, 710061, China
-
The Fourth Hospital of Hebei Medical University
Shijiazhuang, Hebei, 50035, China
-
The Gujarat Cancer & Research Institute (GCRI)
Ahmedabad, Gujarat, 380016, India
-
The Medical Oncology Centre of Rosebank
Johannesburg, Gauteng, 2196, South Africa
-
The Second Affiliate Hospital of Zhejiang University School of medicine
Hangzhou, Zhejiang, 310052, China
-
The first affiliated hospital of China medical university
Shenyang, Liaoning, 110001, China
-
Tianjin Medical University Cancer Institute & Hospital
Tianjin, Tianjin Municipality, China
-
Tongji Hospital Tongji Medical, Science & Technology
Wuhan, Hubei, 430030, China
-
Wuhan Union Hospital Cancer Center
Wuhan, Hubei, 430022, China
-
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, 310022, China